PMID- 25403647
OWN - NLM
STAT- MEDLINE
DCOM- 20150710
LR  - 20220331
IS  - 1468-2079 (Electronic)
IS  - 0007-1161 (Linking)
VI  - 99
IP  - 5
DP  - 2015 May
TI  - Does ocriplasmin affect the RPE-photoreceptor adhesion in macular holes?
PG  - 635-8
LID - 10.1136/bjophthalmol-2014-305620 [doi]
AB  - BACKGROUND: To evaluate the anatomical outcome of patients after vitrectomy due 
      to persisting symptomatic vitreomacular traction (VMT), including full-thickness 
      macular holes (FTMHs) of less than 400 microm, after ocriplasmin treatment. METHODS: 
      Retrospective, single centre, consecutive interventional case series. Patients 
      were treated with a single intravitreal injection of ocriplasmin (Jetrea, 
      Thrombogenics Inc, USA, Alcon/Novartis EU). MAIN OUTCOME MEASURES: resolution of 
      VMT, closure of FTMH and anatomical outcome of vitrectomy after unsuccessful 
      treatment with ocriplasmin. RESULTS: Five patients were treated with ocriplasmin 
      injection. VMT persisted in all but one case. Four patients underwent pars-plana 
      vitrectomy (PPV) for treatment of persistent VMT and FTMH (n=2, size of macular 
      hole <400 microm) in spectral-domain optical coherence tomography (SD-OCT). FTMHs 
      were closed in both cases within the first week postoperatively. After PPV, in 
      three eyes newly developed subretinal fluid was detected, which persisted up to 
      several months postoperatively. CONCLUSIONS: Data on ocriplasmin remain 
      controversial. We report on four cases with resolution of VMT following PPV after 
      unsuccessful ocriplasmin treatment. Newly developed subretinal fluid has been 
      described after ocriplasmin treatment, predominantly in cases with resolution of 
      VMT. We also detected this newly developed subretinal fluid after vitrectomy, 
      which persisted for several weeks up to 7 months in two cases with FTMHs. This 
      may be attributable to loosening of the photoreceptor complex due to enzyme 
      activity of ocriplasmin. Long-term effects of ocriplasmin are still to be 
      evaluated using SD-OCT.
CI  - Published by the BMJ Publishing Group Limited. For permission to use (where not 
      already granted under a licence) please go to 
      http://group.bmj.com/group/rights-licensing/permissions.
FAU - Hager, A
AU  - Hager A
AD  - Department of Ophthalmology, Charite -Universitatsmedizin Berlin, Campus Benjamin 
      Franklin, Berlin, Germany.
FAU - Seibel, I
AU  - Seibel I
AD  - Department of Ophthalmology, Charite -Universitatsmedizin Berlin, Campus Benjamin 
      Franklin, Berlin, Germany.
FAU - Riechardt, A
AU  - Riechardt A
AD  - Department of Ophthalmology, Charite -Universitatsmedizin Berlin, Campus Benjamin 
      Franklin, Berlin, Germany.
FAU - Rehak, M
AU  - Rehak M
AD  - Department of Ophthalmology, Charite -Universitatsmedizin Berlin, Campus Benjamin 
      Franklin, Berlin, Germany.
FAU - Joussen, A M
AU  - Joussen AM
AD  - Department of Ophthalmology, Charite -Universitatsmedizin Berlin, Campus Benjamin 
      Franklin, Berlin, Germany.
LA  - eng
PT  - Journal Article
DEP - 20141117
PL  - England
TA  - Br J Ophthalmol
JT  - The British journal of ophthalmology
JID - 0421041
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Peptide Fragments)
RN  - 7V6HE3DM5A (microplasmin)
RN  - EC 3.4.21.7 (Fibrinolysin)
SB  - IM
MH  - Aged
MH  - Basement Membrane/surgery
MH  - Endotamponade
MH  - Female
MH  - Fibrinolysin/*therapeutic use
MH  - Fibrinolytic Agents/*therapeutic use
MH  - Humans
MH  - Intravitreal Injections
MH  - Male
MH  - Middle Aged
MH  - Peptide Fragments/*therapeutic use
MH  - Photoreceptor Cells, Vertebrate/*metabolism
MH  - Retinal Perforations/*drug therapy/metabolism/surgery
MH  - Retinal Pigment Epithelium/*metabolism
MH  - Retrospective Studies
MH  - Subretinal Fluid
MH  - Tissue Adhesions/drug therapy/metabolism
MH  - Tomography, Optical Coherence
MH  - Visual Acuity
MH  - Vitrectomy
MH  - Vitreous Detachment/etiology
OTO - NOTNLM
OT  - Macula
OT  - Retina
OT  - Vitreous
EDAT- 2014/11/19 06:00
MHDA- 2015/07/15 06:00
CRDT- 2014/11/19 06:00
PHST- 2014/05/31 00:00 [received]
PHST- 2014/10/22 00:00 [accepted]
PHST- 2014/11/19 06:00 [entrez]
PHST- 2014/11/19 06:00 [pubmed]
PHST- 2015/07/15 06:00 [medline]
AID - bjophthalmol-2014-305620 [pii]
AID - 10.1136/bjophthalmol-2014-305620 [doi]
PST - ppublish
SO  - Br J Ophthalmol. 2015 May;99(5):635-8. doi: 10.1136/bjophthalmol-2014-305620. 
      Epub 2014 Nov 17.